Herpes Virus Immunotherapy
HSV infection, with its epidemiological magnitude and physical and psychological effects on the affected, is a major public health issue. The WHO estimated that nearly 70% of the global population aged 15-49 has either HSV-1, HSV-2, or both. This is possible through a unique mechanism in which the virus establishes itself in the host organism (humans): once an infection is established, HSV then initiates lifelong latent infections in the human neuronal cells and lays dormant for the majority of its life cycle.
While HSV is an insidious yet ubiquitous virus that has rendered the biotech and medical communities defenseless for over a century, this group of therapeutic herpes vaccines is expected to provide a functional cure for patients who suffer from HSV-1 and HSV-2 infections. Similar to the ideology behind Zostavax, a live attenuated vaccine that has been successfully used to vaccinate against Herpes Zoster (Shingles) since 2006, ABC believes in tackling the subset of Human Herpes Virus (HSV-1 and HSV2) with the only live attenuated HSV vaccine there is in development.
Both of the live-attenuated HSV-1 and HSV-2 therapeutics were under research and development at Southern Illinois University in the US for almost 20 years, and proven in published academic studies to be 50x more effective than subunit D vaccines, the leading vaccine candidates in the industry. The primary investigators successfully completed and replicated numerous animal model studies that demonstrated safety and immunogenicity.
With hopes for an effective vaccine, we expect the HSV-1 therapeutic vaccine to show crossover effects in effectively treating HSV-2 infections, and vice versa, as the two viruses share homology of over 80%.
*Note: For complete description of therapeutics and diagnostics with citations, please refer to ABC ICO Prospectus